BeOne Medicines (HKSE:06160) Price-to-Tangible-Book : 9.56 (As of Jul. 20, 2025)

View and export this data going back to 2018. Start your Free Trial

What is BeOne Medicines Price-to-Tangible-Book?

As of today (2025-07-20), BeOne Medicines's share price is HK$182.70. BeOne Medicines's Tangible Book per Share of Mar. 2025 for the quarter that ended in Mar. 2025 was HK$19.11. Hence, BeOne Medicines's Price to Tangible Book Ratio of today is 9.56.

The historical rank and industry rank for BeOne Medicines's Price-to-Tangible-Book or its related term are showing as below:

HKSE:06160' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.03 Med: 5.41 Max: 11.24
Current: 9.22

During the past 12 years, BeOne Medicines's highest Price to Tangible Book Ratio was 11.24. The lowest was 3.03. And the median was 5.41.

HKSE:06160's Price-to-Tangible-Book is ranked worse than
81.13% of 1203 companies
in the Biotechnology industry
Industry Median: 3.17 vs HKSE:06160: 9.22

A closely related ratio is called PB Ratio. As of today, BeOne Medicines's share price is HK$182.70. BeOne Medicines's Book Value per Sharefor the quarter that ended in Mar. 2025 was HK$19.38. Hence, BeOne Medicines's P/B Ratio of today is 9.43.

BeOne Medicines Price-to-Tangible-Book Historical Data

The historical data trend for BeOne Medicines's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines Price-to-Tangible-Book Chart

BeOne Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Tangible-Book

Get a 7-Day Free Trial

6.35

4.57

5.45

5.57

6.10

BeOne Medicines Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Tangible-Book	Get a 7-Day Free Trial															5.00	4.58	7.58	6.10	8.70

Competitive Comparison of BeOne Medicines's Price-to-Tangible-Book

For the Biotechnology subindustry, BeOne Medicines's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeOne Medicines's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

BeOne Medicines Price-to-Tangible-Book Calculation

BeOne Medicines's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2025 )
	=	182.70	/	19.106
	=	9.56

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

BeOne Medicines Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

BeOne Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (HKSE:06160) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 49B:Germany 688235:China B1ME34:Brazil

Address

c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051

Website

https://www.beonemedicines.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

Executives

Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2502 Approved lending agent
Oyler John Victor	2101 Beneficial owner
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeOne Medicines Headlines

No Headlines